{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:32:53Z","timestamp":1793017973847,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jconrel.2022.12.048","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:20:04Z","timestamp":1672896004000},"page":"91-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy"],"prefix":"10.1016","volume":"354","author":[{"given":"Saad N.","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Su","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cedrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry W.","family":"Neun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Dobrovolskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap Ching","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunggul","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jik","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0005","article-title":"Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Critical reviewsTM","volume":"40","author":"Waite","year":"2012","journal-title":"Biomed. Eng."},{"issue":"14","key":"10.1016\/j.jconrel.2022.12.048_bb0010","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0959-8049(99)00280-4","article-title":"Discovering novel chemotherapeutic drugs for the third millennium","volume":"35","author":"Garrett","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2022.12.048_bb0015","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/jbm.a.36410","article-title":"Combinational drug delivery using nanocarriers for breast cancer treatments: a review","volume":"106","author":"Olov","year":"2018","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"11","key":"10.1016\/j.jconrel.2022.12.048_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.35","article-title":"Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy","volume":"4","author":"Borah","year":"2015","journal-title":"Oncogenesis."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0025","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","year":"2018"},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","article-title":"Nanomedicine: current status and future prospects","volume":"19","author":"Moghimi","year":"2005","journal-title":"FASEB J."},{"issue":"27","key":"10.1016\/j.jconrel.2022.12.048_bb0035","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1016\/j.biomaterials.2012.05.046","article-title":"Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials."},{"issue":"17","key":"10.1016\/j.jconrel.2022.12.048_bb0040","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.biomaterials.2009.03.006","article-title":"Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect","volume":"30","author":"Wiradharma","year":"2009","journal-title":"Biomaterials."},{"issue":"28","key":"10.1016\/j.jconrel.2022.12.048_bb0045","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1039\/c2sm25456e","article-title":"Reduction-responsive shell-crosslinked micelles prepared from Y-shaped amphiphilic block copolymers as a drug carrier","volume":"8","author":"Yue","year":"2012","journal-title":"Soft Matter"},{"issue":"21","key":"10.1016\/j.jconrel.2022.12.048_bb0050","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1021\/ja211888a","article-title":"Photoswitchable nanoparticles for triggered tissue penetration and drug delivery","volume":"134","author":"Tong","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0055","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1021\/bm200604h","article-title":"Folic acid conjugated amino acid-based star polymers for active targeting of cancer cells","volume":"12","author":"Sulistio","year":"2011","journal-title":"Biomacromolecules."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0065","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.surfrep.2017.02.001","article-title":"Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications","volume":"72","author":"Heinz","year":"2017","journal-title":"Surf. Sci. Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/joim.13254","article-title":"Nanotechnology for modern medicine: next step towards clinical translation","volume":"290","author":"Sindhwani","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: principles, properties, and regulatory issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0085","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.2147\/IJN.S132780","article-title":"High drug-loading nanomedicines: progress, current status, and prospects","volume":"12","author":"Shen","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0095","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2022.12.048_bb0110","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/jps.21270","article-title":"Nanovehicular intracellular delivery systems","volume":"97","author":"Prokop","year":"2008","journal-title":"J. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.biomaterials.2009.09.101","article-title":"The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents","volume":"31","author":"Sahay","year":"2010","journal-title":"Biomaterials."},{"issue":"12","key":"10.1016\/j.jconrel.2022.12.048_bb0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0167-7799(00)89017-4","article-title":"Engineering liposomes for drug delivery: progress and problems","volume":"13","author":"Gregoriadis","year":"1995","journal-title":"Trends Biotechnol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.12.048_bb0125","article-title":"Thermosensitive liposomes for localized delivery and triggered release of chemotherapy","volume":"169","author":"Ta","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymeth.2019.11.007","article-title":"Extracellular blebs: artificially-induced extracellular vesicles for facile production and clinical translation","volume":"177","author":"Thone","year":"2020","journal-title":"Methods."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.018","article-title":"Advanced drug delivery 2020 and beyond: perspectives on the future","volume":"158","author":"Bae","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0145","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2022.12.048_bb0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/molecules25071539","article-title":"New developments in medical applications of hybrid hydrogels containing natural polymers","volume":"25","author":"Vasile","year":"2020","journal-title":"Molecules."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0155","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/bi00462a016","article-title":"Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin","volume":"29","author":"Frederick","year":"1990","journal-title":"Biochemistry."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0160","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/acsami.6b00461","article-title":"Molecularly imprinted polymers with DNA aptamer fragments as macromonomers","volume":"8","author":"Zhang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fphar.2017.00224","article-title":"Pharmacological activity and clinical use of PDRN","volume":"8","author":"Squadrito","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0170","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jvs.2008.06.041","article-title":"Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease","volume":"48","author":"Bitto","year":"2008","journal-title":"J. Vasc. Surg."},{"issue":"8","key":"10.1016\/j.jconrel.2022.12.048_bb0175","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1021\/nn200693a","article-title":"Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy","volume":"5","author":"Chang","year":"2011","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.jconrel.2022.12.048_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136673","article-title":"A synthetic aptamer-drug adduct for targeted liver cancer therapy","volume":"10","author":"Trinh","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4155\/tde-2021-0038","article-title":"Targeted delivery of doxorubicin through CD44 aptamer to cancer cells","volume":"12","author":"Natesh","year":"2021","journal-title":"Ther. Deliv."},{"issue":"31","key":"10.1016\/j.jconrel.2022.12.048_bb0190","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.1021\/acs.jpcb.1c03193","article-title":"Silinanyl rhodamines and silinanyl fluoresceins for super-resolution microscopy","volume":"125","author":"Hara","year":"2021","journal-title":"J. Phys. Chem. B"},{"issue":"11","key":"10.1016\/j.jconrel.2022.12.048_bb0195","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050202","article-title":"Iron loss triggers mitophagy through induction of mitochondrial ferritin","volume":"21","author":"Hara","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0200","article-title":"virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation","author":"Li","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"16","key":"10.1016\/j.jconrel.2022.12.048_bb0205","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1093\/bioinformatics\/btu202","article-title":"ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging","volume":"30","author":"Ovesn\u00fd","year":"2014","journal-title":"Bioinformatics."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0210","series-title":"Method for Analysis of Nanoparticle Hemolytic Properties In Vitro, in Characterization of Nanoparticles Intended for Drug Delivery","first-page":"215","author":"Neun","year":"2011"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0215","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-7352-1_9","article-title":"Updated method for in vitro analysis of nanoparticle hemolytic properties, in characterization of nanoparticles intended for drug delivery","volume":"vol. 1628","author":"Neun","year":"2018"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0220","series-title":"NCL Method ITA-1: Analysis of Hemolytic Properties of Nanoparticles","author":"Neun","year":"2022"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0225","series-title":"Method for In Vitro Analysis of Nanoparticle Thrombogenic Properties, in Characterization of Nanoparticles Intended for Drug Delivery","first-page":"225","author":"Neun","year":"2011"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0230","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-4939-7352-1_10","article-title":"In vitro assessment of nanoparticle effects on blood coagulation, in characterization of nanoparticles intended for drug delivery","volume":"vol. 1628","author":"Potter","year":"2018"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0235","series-title":"NCL Method ITA-2.1: Analysis of Platelet Aggregation by Cell Counting","author":"Neun","year":"2022"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0240","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-7352-1_13","article-title":"Analysis of complement activation by nanoparticles, in characterization of nanoparticles intended for drug delivery","volume":"vol. 1628","author":"Neun","year":"2018"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0245","series-title":"NCL method ITA-5.2: analysis of Complement Activation by Single-Plex EIA or Multiplex ELISA","author":"Neun","year":"2022"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0250","series-title":"NCL Method ITA-12: In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time","author":"Cedrone","year":"2022"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0255","series-title":"NCL Method-10: Preparation of Human Whole Blood and periPheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro","author":"Potter","year":"2022"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0260","series-title":"NCL Method ITA-27: Multiplex Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human Cytokines in Culture Supernatants","author":"Cedrone","year":"2022"},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0265","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/acs.bioconjchem.9b00822","article-title":"Biocompatible chemotherapy for leukemia by acid-cleavable, PEGylated FTY720","volume":"31","author":"Kemp","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0270","author":"Benefits of Nanotechnology for Cancer \u2013 National Cancer Institute"},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"issue":"45","key":"10.1016\/j.jconrel.2022.12.048_bb0285","article-title":"Trisulfide bond\u2013mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity. Science","volume":"6","author":"Yang","year":"2020","journal-title":"Advances."},{"issue":"47","key":"10.1016\/j.jconrel.2022.12.048_bb0290","doi-asserted-by":"crossref","first-page":"11160","DOI":"10.1039\/c3sm52157e","article-title":"Strand displacement in DNA-based materials systems","volume":"9","author":"Baker","year":"2013","journal-title":"Soft Matter"},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0295","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/jmbi.2000.3573","article-title":"The kinetics of oligonucleotide replacements","volume":"297","author":"Reynaldo","year":"2000","journal-title":"J. Mol. Biol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.12.048_bb0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0009-2797(84)90061-9","article-title":"Identification of the specific sites of interaction between intercalating drugs and DNA","volume":"49","author":"Robbie","year":"1984","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.jconrel.2022.12.048_bb0305","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1039\/C8OB02344A","article-title":"Investigations into the DNA-binding mode of doxorubicinone","volume":"17","author":"Tartakoff","year":"2019","journal-title":"Org. Biomol. Chem."},{"issue":"7","key":"10.1016\/j.jconrel.2022.12.048_bb0310","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1046\/j.1432-1327.2001.02107.x","article-title":"High affinity binding of paclitaxel to human serum albumin","volume":"268","author":"Pa\u00e1l","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"153","key":"10.1016\/j.jconrel.2022.12.048_bb0315","first-page":"1","article-title":"Quality-by-design concepts to improve nanotechnology-based drug development","volume":"36","author":"Rawal","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0320","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jconrel.2020.10.014","article-title":"Carrier-free nanodrugs for safe and effective cancer treatment","volume":"329","author":"Karaosmanoglu","year":"2021","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2022.12.048_bb0325","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1021\/nn404501g","article-title":"Facing the truth about nanotechnology in drug delivery","volume":"7","author":"Park","year":"2013","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0330","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1002\/ange.202009842","article-title":"A tubular DNA nanodevice as a siRNA\/chemo-drug co-delivery vehicle for combined cancer therapy","volume":"133","author":"Wang","year":"2021","journal-title":"Angew. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0335","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1039\/D1NA00753J","article-title":"Loading of DOX into a tetrahedral DNA nanostructure: the corner does matter","volume":"4","author":"Xu","year":"2022","journal-title":"Nanoscale Adv."},{"issue":"6","key":"10.1016\/j.jconrel.2022.12.048_bb0340","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/nar\/gkab097","article-title":"Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release","volume":"49","author":"Ij\u00e4s","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0345","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/IJN.S38378","article-title":"Nanodrugs: pharmacokinetics and safety","volume":"9","author":"Onoue","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100074","article-title":"Can the union of prodrug therapy and nanomedicine lead to better cancer management?","volume":"2","author":"Muthiah","year":"2022","journal-title":"Adv. NanoBiomed. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0355","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-2272-7_3","article-title":"Getting across the cell membrane: an overview for small molecules, peptides, and proteins","author":"Yang","year":"2015","journal-title":"Site-Specif. Protein Label."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0365","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tiv.2014.12.009","article-title":"Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells","volume":"29","author":"Wojcik","year":"2015","journal-title":"Toxicol. in Vitro"},{"issue":"9","key":"10.1016\/j.jconrel.2022.12.048_bb0370","doi-asserted-by":"crossref","DOI":"10.2174\/1389200219666180611080736","article-title":"Recent advances in gold nanoformulations for cancer therapy","volume":"19","author":"Shevtsov","year":"2018","journal-title":"Curr. Drug Metab."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0375","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0380","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.2147\/IJN.S274289","article-title":"Endocytosis and organelle targeting of nanomedicines in cancer therapy","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0385","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0390","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The endosomal escape of nanoparticles: toward more efficient cellular delivery","volume":"30","author":"Smith","year":"2018","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202270015","article-title":"Understanding the biological interactions of pH-Swellable nanoparticles","volume":"22","author":"Kermaniyan","year":"2022","journal-title":"Macromol. Biosci."},{"issue":"7","key":"10.1016\/j.jconrel.2022.12.048_bb0400","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/ar3000162","article-title":"Nucleic acid delivery: the missing pieces of the puzzle?","volume":"45","author":"Nguyen","year":"2012","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-14928-3","article-title":"Macropinocytosis confers resistance to therapies targeting cancer anabolism","volume":"11","author":"Jayashankar","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2022.12.048_bb0410","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbamem.2016.04.014","article-title":"Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes","volume":"1858","author":"Li","year":"2016","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"22","key":"10.1016\/j.jconrel.2022.12.048_bb0415","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.3390\/ijms21228503","article-title":"Binding of RNA aptamers to membrane lipid rafts: implications for exosomal miRNAs transfer from cancer to immune cells","volume":"21","author":"Janas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.jconrel.2022.12.048_bb0420","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1073\/pnas.1305804110","article-title":"Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates","volume":"110","author":"Choi","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0425","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52012","article-title":"A molecular view on the escape of lipoplexed DNA from the endosome","volume":"9","author":"Bruininks","year":"2020","journal-title":"Elife."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0430","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2020.09.007","article-title":"Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine","volume":"327","author":"Yamada","year":"2020","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2022.12.048_bb0435","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.biomaterials.2013.10.034","article-title":"The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0440","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1039\/C6NR07866D","article-title":"Investigation and intervention of autophagy to guide cancer treatment with nanogels","volume":"9","author":"Zhang","year":"2017","journal-title":"Nanoscale."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201603276","article-title":"Black phosphorus nanosheets as a robust delivery platform for cancer theranostics","volume":"29","author":"Tao","year":"2017","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.jconrel.2022.12.048_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000572","article-title":"Autophagy and doxorubicin resistance in cancer","volume":"29","author":"Chen","year":"2018","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2022.12.048_bb0455","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11897-021-00519-w","article-title":"The interplay between autophagy and senescence in anthracycline cardiotoxicity","volume":"18","author":"Russo","year":"2021","journal-title":"Current Heart Fail. Rep."},{"issue":"4","key":"10.1016\/j.jconrel.2022.12.048_bb0460","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2017.1380655","article-title":"Advances in nano-delivery systems for doxorubicin: an updated insight","volume":"26","author":"Kanwal","year":"2018","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0465","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0470","first-page":"2401","article-title":"Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.12.048_bb0475","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jconrel.2022.12.048_bb0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0039-1687890","article-title":"Disseminated intravascular coagulation in cancer: an update","volume":"45","author":"Levi","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.jconrel.2022.12.048_bb0485","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2009.03300.x","article-title":"Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes","volume":"7","author":"Swystun","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1096\/fj.03-0646fje","article-title":"Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas (lpr) mice","volume":"18","author":"Anders","year":"2004","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0495","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ni1282","article-title":"A toll-like receptor\u2013independent antiviral response induced by double-stranded B-form DNA","volume":"7","author":"Ishii","year":"2006","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0500","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/exd.12603","article-title":"Cp GB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin","volume":"24","author":"Mathes","year":"2015","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0505","first-page":"41","article-title":"Repeated remote ischemic conditioning reduces doxorubicin-induced cardiotoxicity","volume":"2","author":"He","year":"2020","journal-title":"Cardio Oncol."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0510","article-title":"Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation","author":"Wilkinson","year":"2019","journal-title":"Biorxiv."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0515","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1084\/jem.188.3.609","article-title":"HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3","volume":"188","author":"Hadida","year":"1998","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2022.12.048_bb0520","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/intimm\/12.8.1173","article-title":"RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation","volume":"12","author":"Appay","year":"2000","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.12.048_bb0525","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/1043-4666(91)90013-4","article-title":"Biology of the RANTES\/SIS cytokine family","volume":"3","author":"Schall","year":"1991","journal-title":"Cytokine."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0530","series-title":"Chemokines in Disease: Biology and Clinical Research","author":"Herbert","year":"1999"},{"issue":"6","key":"10.1016\/j.jconrel.2022.12.048_bb0535","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI3986","article-title":"CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines","volume":"102","author":"Kim","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.jconrel.2022.12.048_bb0540","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.4139","article-title":"Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2022.12.048_bb0545","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.cell.2016.10.017","article-title":"A functional genomics approach to understand variation in cytokine production in humans","volume":"167","author":"Li","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0550","author":"NIH US Nation Library of Medicine"},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0555","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jcpe.12010","article-title":"Adenosine receptor stimulation by polynucleotides (PDRN) reduces inflammation in experimental periodontitis","volume":"40","author":"Bitto","year":"2013","journal-title":"J. Clin. Periodontol."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0560","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fphar.2018.00506","article-title":"Activation of A2A receptor by PDRN reduces neuronal damage and stimulates WNT\/\u03b2-catenin driven neurogenesis in spinal cord injury","volume":"9","author":"Irrera","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0565","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/60.1.177","article-title":"Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier","volume":"60","author":"Goodwin","year":"2001","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0570","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00273522","article-title":"Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin","volume":"23","author":"Balazsovits","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"20","key":"10.1016\/j.jconrel.2022.12.048_bb0575","doi-asserted-by":"crossref","first-page":"20817","DOI":"10.18632\/aging.104056","article-title":"Hippocampal and cortical tissue-specific epigenetic clocks indicate an increased epigenetic age in a mouse model for Alzheimer\u2019s disease","volume":"12","author":"Coninx","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01029-1","article-title":"Clinical evaluation of bladder CARE, a new epigenetic test for bladder cancer detection in urine samples","volume":"13","author":"Piatti","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.jconrel.2022.12.048_bb0585","series-title":"Pharmacoepigenetics","first-page":"837","article-title":"Epigenetics in doxorubicin cardiotoxicity","author":"Ferreira","year":"2019"},{"issue":"26","key":"10.1016\/j.jconrel.2022.12.048_bb0590","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1922072117","article-title":"Uncoupling DNA damage from chromatin damage to detoxify doxorubicin","volume":"117","author":"Qiao","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.12.048_bb0595","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jconrel.2022.12.048_bb0600","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/emm.2006.63","article-title":"Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0041-008X(91)90336-D","article-title":"Mitochondrial regulation of superoxide by Ca2+: an alternate mechanism for the cardiotoxicity of doxorubicin","volume":"107","author":"Chacon","year":"1991","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"11","key":"10.1016\/j.jconrel.2022.12.048_bb0610","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1111\/jcmm.14637","article-title":"Sodium hydrosulphide restores tumour necrosis factor-\u03b1-induced mitochondrial dysfunction and metabolic dysregulation in HL-1 cells","volume":"23","author":"Lee","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.12.048_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5487\/TR.2014.30.1.001","article-title":"Human tumor xenograft models for preclinical assessment of anticancer drug development","volume":"30","author":"Jung","year":"2014","journal-title":"Toxicol. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2022.12.048_bb0625","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2249.2008.03753.x","article-title":"Non-obese diabetic\u2013recombination activating gene-1 (NOD\u2013rag 1 null) interleukin (IL)-2 receptor common gamma chain (IL 2 r\u03b3null) null mice: a radioresistant model for human lymphohaematopoietic engraftment","volume":"154","author":"Pearson","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"6292","key":"10.1016\/j.jconrel.2022.12.048_bb0630","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/347479a0","article-title":"The scid mutation in mice causes a general defect in DNA repair","volume":"347","author":"Fulop","year":"1990","journal-title":"Nature."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:33:20Z","timestamp":1759163600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922008616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":125,"alternative-id":["S0168365922008616"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.048","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}